Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Eli Lilly has launched Mounjaro in India, a groundbreaking weight loss and diabetes drug, at a fraction of its US price. The ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Lilly's revenue and earnings have been growing much faster than those of most of its similarly sized peers in the healthcare industry, so it only makes sense that it has a higher forward P/E.

Eli Lilly LLY-0.27%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...

For example, the Eli Lilly and Company (NYSE ... This optimism is visible in its fairly high P/E ratio of 74.10. The image below shows how EPS has tracked over time (if you click on the image ...